



ASX ANNOUNCEMENT

Expiry of Performance Shares

Perth, Australia; 1 September 2020. NeuroScientific Biopharmaceuticals Ltd ASX: NSB ("NeuroScientific" or "the Company") wishes to advise of the expiry of 700,000 unlisted performance shares (Class B), on 26 August 2020.

The performance shares expired without converting to ordinary shares, as a result of the associated milestone for the Class B performance shares not being met within 2 years of the date that the company was admitted to the ASX.

About Neuroscientific Biopharmaceuticals Limited

NeuroScientific Biopharmaceuticals (ASX:NSB) is a company developing peptide-based pharmaceutical drugs that target a number of neurodegenerative conditions with high unmet medical demand. The company's product portfolio includes EmtinB, a therapeutic peptide initially targeting Alzheimer's disease and glaucoma, as well as other Emtin peptides (EmtinAc, EmtinAn, and EmtinBn) which have demonstrated similar therapeutic potential as EmtinB. For more information, please visit www.neuroscientific.com

END

Announcement authorised by the Board of Directors of NeuroScientific Biopharmaceuticals

Contacts

Matthew Liddelow
CEO and Managing Director
ml@neuroscientific.com
+61 8 6382 1805

Brian Leedman
Non-executive Chairman
bl@neuroscientific.com
+61 412 281 780